[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521519":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":42,"centralContacts":46,"locations":55,"responsibleParty":73,"collaborators":76,"id":80,"slug":41,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":41,"eligibilityCriteria":84,"healthyVolunteers":81,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":41,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":41,"overallStatus":58,"whyStopped":41,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Yale University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Group 1","ACTIVE_COMPARATOR","Bolus of 0.3mg\u002Fkg\u002Fmin DMT (5min) + Normal Saline infusion (60 min)",[13],"Drug: 0.3mg\u002Fkg\u002Fmin Dimethyltryptamine + Normal Saline infusion",{"label":15,"type":10,"description":16,"interventionNames":17},"Group 2","Bolus of 0.2 mg\u002Fkg\u002Fmin DMT (5 min) + 0.01mg\u002Fkg\u002Fmin infusion (60 min)",[18],"Drug: 0.2 mg\u002Fkg\u002Fmin + Dimethyltryptamine 0.01mg\u002Fkg\u002Fmin infusion",{"label":20,"type":21,"description":22,"interventionNames":23},"Group 3","PLACEBO_COMPARATOR","Bolus of 25 mg Diphenhydramine (5 min) + Normal Saline infusion (60 min)",[24],"Drug: 25 mg Diphenhydramine (5 min) + Normal Saline",[26,33,38],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","0.3mg\u002Fkg\u002Fmin Dimethyltryptamine + Normal Saline infusion","Infusion",[9],[32],"Moderate Dose DMT",{"type":27,"name":34,"description":29,"armGroupLabels":35,"otherNames":36},"0.2 mg\u002Fkg\u002Fmin + Dimethyltryptamine 0.01mg\u002Fkg\u002Fmin infusion",[15],[37],"Low Dose DMT",{"type":27,"name":39,"description":29,"armGroupLabels":40,"otherNames":41},"25 mg Diphenhydramine (5 min) + Normal Saline",[20],null,[43],{"name":44,"affiliation":5,"role":45},"Anahita Bassir Nia, MD","PRINCIPAL_INVESTIGATOR",[47,52],{"name":48,"role":49,"phone":50,"phoneExt":41,"email":51},"Angelina Contreras","CONTACT","(203) 974-7525","angelina.contreras@yale.edu",{"name":53,"role":49,"phone":41,"phoneExt":41,"email":54},"Ardavan Mohammad Aghaei","ardavan.mohammadaghaei@yale.edu",[56],{"facility":57,"status":58,"city":59,"state":60,"zip":61,"country":62,"cosmosGeoPoint":63,"geoPoint":68,"contacts":69},"Connecticut Mental Health Center","RECRUITING","New Haven","Connecticut","06519","United States",{"type":64,"coordinates":65},"Point",[66,67],-72.92816,41.30815,{"lat":67,"lon":66},[70,72],{"name":44,"role":49,"phone":41,"phoneExt":41,"email":71},"anahita.bassirnia@yale.edu",{"name":44,"role":45,"phone":41,"phoneExt":41,"email":41},{"type":45,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":41,"oldOrganization":41},"Anahita Bassir Nia","Assistant Professor of Psychiatry",[77],{"name":78,"class":79},"National Institute on Alcohol Abuse and Alcoholism (NIAAA)","NIH","100521519",false,"NCT06070649","The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)","Inclusion Criteria:\n\n* Diagnostic and Statistical Manual of Mental Disorders-5th edition (DSM-5) diagnosis of Alcohol Use Disorder\n* Medically healthy\n* Ability to provide consent\n\nExclusion Criteria:\n\n* Unstable medical conditions","ALL","21 Years","65 Years",{"count":89,"type":90},63,"ESTIMATED","INTERVENTIONAL",[93],"PHASE1","This proposed study is a double-blind, randomized, placebo-controlled, parallel-group, laboratory study to determine the effects of DMT, plus psychotherapy, on Alcohol Use Disorder.",[96,97,98],"Alcohol Use Disorder (AUD)","Alcohol-Related Disorders","Alcohol Use","2026-04-26",{"date":101,"type":102},"2026-04-28","ACTUAL",{"date":104,"type":102},"2025-08-04",{"date":106,"type":90},"2026-08-01",{"name":5,"class":6},1]